Simón-Campos JA, Padilla-Hernández RO

Language: Spanish
References: 17
Page: 591-596
PDF size: 305.70 Kb.

ABSTRACT

Objective: to compare the correlation between C reactive protein (CRP) and erythrosedimentation rate (ESR) with rheumatoid arthritis (RA) activity.
Methods: cross-sectional study, in patients with RA. All were assessed by a rheumatologist who evaluated the RA disease activity according to the American College of Rheumatology score. Blood sample was dropped to test CRP and ESR levels. The correlation between CRP and ESR with RA disease activity was estimated using rho Spearman coefficient.
Results: we included 80 patients, mean age of 50.5 ± 11.0 years. 62.5 % had some degree of disease activity. We found that CRP had a high correlation with all parameters of disease activity included: number of tenders joins (r = 0.352, p = 0.001), number of painful joins (r = 0.327, p = 0.003), VAS of join pain (r = 0.385, p ‹ 0.0001), VAS of global disease activity estimated by the patient (r = 0.325, p = 0.003), VAS of global disease activity estimated by the rheumatologist (r = 0.486, p ‹ 0.0001), and HAQ score (r = 0.310, p = 0.005). In contrast the ESR only had correlation with the HAQ score (r = 0.310, p = 0.005).
Conclusions: Our results suggest that CRP is a better test to support the clinical evaluation of disease activity in RA.

REFERENCES

1. Simón JA. Biological therapy in rheumatoid arthritis. Rev Invest Clin 2001;53:452-459.

2. Le Loet X, Berthelot JM, Cantagrel A. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis 2006;65:45-50.

3. Young A. Early rheumatoid arthritis. Rheum Dis Clin North Am 2005;31:659-679.

4. Suresh E, Lambert CM. Combination treatment strategies in early rheumatoid arthritis. Ann Rheum Dis 2005;64:1252-1256.

5. Cardiel MH. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology 2006;45:7-22.

6. Emery P. Treatment of rheumatoid arthritis. BMJ 2006;332:152-155.

7. Díaz-Jouanen E, Abud-Mendoza C, Garza-Elizondo MA. Recommendations for the medical treatment of rheumatoid arthritis. Rev Invest Clin. 2006;58:80.

8. Mierau R, Genth E. Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis. Clin Chem Lab Med 2006; 44:138-143.

9. Visser H. Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:55-72.

10. Yildirim K, Karatay S, Melikoglu MA. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci 2004;34:423-426.

11. Dessein PH, Joffe BI, Stanwix AE. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol 2004;31:1095-1097.

12. Ward MM. Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. J Rheumatol 2004;31:838-840.

13. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997; 24:1477-1485.

14. Devlin J, Gough A, Huissoon A. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 1998;25:602-603.

15. Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994;24:91-104.

16. Arnett FC, Bedworth SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.

17. Felon DT, Anderson JJ, Boers M. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735.